WalkingDread
Posted - 16 minutes ago
$PPBT 3/4 stable disease in low dose monotherapy (3 - 24mg/kg)reported in 2022. Ill stick around to see what current dosing(100mg) produces.
sbrino
Posted - 21 minutes ago
$PPBT c tres is on here an awful lot, wonder how man shares he has? 😽
Ctres06
Posted - 32 minutes ago
$PPBT volume is huge! Must be the great news we got this morning.
Sleepwhndead
Posted - 44 minutes ago
$PPBT they need to show something AMAZING and soon! Cause if not, we won’t last long enough before a RS is forced to wait for something good
hughjazz15
Posted - 57 minutes ago
$PPBT my prediction, good news, stonk go down
Stocksidobet
Posted - 59 minutes ago
$PPBT we gonna leavege this thick dick on you 😂😂😂
FBP
Posted - 1 hour ago
$PPBT if it aint topline market won't care I'm betting. Good to show this at the upcoming conference but the needle needs to be bigger is my guess.
Sleepwhndead
Posted - 1 hour ago
$PPBT we were also told “rapid ROI” and “monumental year” for a long time lol
Oh and “cash runway” All have been lies
YamiDawg
Posted - 1 hour ago
$PPBT Scanners in pre. Lol. Go bears. 10%.
Dr_HIM
Posted - 1 hour ago
$PPBT
Covence
Posted - 1 hour ago
$PPBT NEW DATA 🚨
“At AACR 2024 we will present new data related to NT219. We show for the first time the potential of NT219 to effectively suppress cancer stem cells (CSC), a critical cell population for tumor propagation, characterized by self-renewal and multipotency, and known to promote resistance and tumor recurrence.”
LuckyBoy369
Posted - 1 hour ago
$PPBT Be Ready for spike Dr Hadas Reuveni, VP Research and Development at Purple Biotech, added, "At AACR 2024 we will present new data related to NT219. We show for the first time the potential of NT219 to effectively suppress cancer stem cells (CSC), a critical cell population for tumor propagation, characterized by self-renewal and multipotency, and known to promote resistance and tumor recurrence
allgoodstill
Posted - 1 hour ago
$PPBT Hopefully some of his real 12k followers will notice something of interest here.🤷♂️
PPBT4LYFE
Posted - 1 hour ago
$PPBT I didn’t realize it was preclinical again. Gdammit.
LuckyBoy369
Posted - 1 hour ago
$PPBT Major pump incoming. All Abroad
We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.
PPBT4LYFE
Posted - 1 hour ago
$PPBT I’m not a playa I just crush a lot.
roachfood
Posted - 1 hour ago
$PPBT “We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.”
Key word for me here is “leveraging” and what route they take to do that.
lilc1477
Posted - 1 hour ago
$PPBT This is long overdue for a pump. $15 million market cap for a company with multiple Phase II drugs in hard to treat cancers with unmet medical needs. This deserves a little love
YamiDawg
Posted - 1 hour ago
$PPBT
vinland
Posted - 1 hour ago
$PPBT Now to make it happen, talk is cheap. Gil last year - I think our future will primarily involve leveraging data that we generate to be able to raise more capital and expand the programs or add assets. Gil today - We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.
Ctres06
Posted - 1 hour ago
$PPBT those abstracts are not going to do anything for the stock price. It's embarrassing that we have been here this long and we are presenting preclinical data and phase 1 biomarker data. No actual clinical data coming.
KITOVLI
Posted - 1 hour ago
$PPBT $1
Sleepwhndead
Posted - 2 hours ago
$PPBT if this next conference and data presentation isn’t INSANELY AMAZING, then just start preparing for the REVERSE SPLIT… we are running out of money with almost no tutes interested in being involved with us. If the data does nothing for us and it’s not mind blowing, the next reverse split will wipe out current shareholders as it’ll be the 2nd one for most
Stocktelligence
Posted - 2 hours ago
$PPBT me like it We show for the first time the potential of NT219 to effectively suppress cancer stem cells (CSC), a critical cell population for tumor propagation, characterized by self-renewal and multipotency, and known to promote resistance and tumor recurrence. In addition, synergistic effect of NT219 and mKRAS inhibitors is demonstrated, suggesting a novel mechanism to combat resistance to both KRASG12Cand KRAS KRASG12D inhibitors in lung cancer and pancreatic cancers, respectively, both aggressive diseases with unmet medical need. In another presentation, we show the results of translational research in our Phase 1 study, suggesting activated IGF1R and STAT3 as potential biomarkers for the treatment with NT219
Watcher76
Posted - 2 hours ago
$PPBT Purple is looking a lot better today!
DonCorleone77
Posted - 2 hours ago
$PPBT Purple Biotech to present data on NT219 at AACR 2024 Purple Biotech announced it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research, AACR, annual meeting which takes place April 5-11, 2024, in San Diego, California. "The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers. These publications at AACR 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219's attributes," stated Gil Efron, Chief Executive Officer of Purple Biotech. "We look forward to leveraging these data as we move forward with the clinical evaluation of NT219."
Richgreenz
Posted - 2 hours ago
$PPBT 🥹
Wkdwalker
Posted - 2 hours ago
$PPBT data we are waiting for 😎
kckc88
Posted - 3 hours ago
$PPBT I thought it was gonna be cm24 data we would be presenting in April 🤔 let’s goooooo!!!!
ksmithwnc
Posted - 3 hours ago
$PPBT this one seems significant